论文部分内容阅读
为阐明不同类型红细胞增多症病人中组织纤溶酶原(t-PA)在血栓栓塞中的作用,作者检查了86例这类患者的血浆中t-PA抗原浓度。其中29例为真性红细胞增多症(PV),11例为继发性红细胞增多,46例为假性红细胞增多。另选24例相同年龄的健康者作对照。15例有血栓栓塞性疾病(TED)病史的患者中有7例表现为心肌梗塞,5例为脑血管血栓形成,3例为深静脉血栓形成。除假性红细胞增多组TED占17％外,其余两组中TED均占18％。所有患者均取静脉血,分离血浆后用ELISA法检测t-PA-抗原和显色法检测纤溶酶原活化剂的抑制剂(PAI)。结果:对照组血浆t-PA-抗原浓度与以前报道相同。PV组患者t-PA-抗原明显低于对照组(P=
To clarify the role of tissue plasminogen (t-PA) in thromboembolism in patients with different types of polycythemia, the authors examined the plasma concentration of t-PA antigen in 86 patients. 29 cases of polycythemia vera (PV), 11 cases of secondary erythrocytosis, 46 cases of pseudo-erythrocytosis. Another 24 healthy subjects of the same age as control. Seven of 15 patients with a history of thromboembolic disease (TED) presented with myocardial infarction, 5 with cerebrovascular thrombosis and 3 with deep venous thrombosis. Except for 17% of TEDs in the group of pseudocytosis, TED accounted for 18% of the other two groups. Venous blood was taken from all patients, plasma was separated and t-PA-antigen was detected by ELISA and plasminogen activator inhibitor (PAI) by chromogenic assay. Results: The plasma t-PA-antigen concentration in the control group was the same as previously reported. The t-PA-antigen in PV group was significantly lower than that in control group (P =